trimethoprim has been researched along with Marchiafava-Micheli Syndrome in 1 studies
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.
trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kuwabara, H | 1 |
| Miura, S | 1 |
| Takahashi, H | 1 |
| Takada, M | 1 |
| Uehara, M | 1 |
| Saito, S | 1 |
| Kurihara, M | 1 |
| Nemoto, T | 1 |
| Kobayashi, S | 1 |
1 other study available for trimethoprim and Marchiafava-Micheli Syndrome
| Article | Year |
|---|---|
[Paroxysmal hemoglobinuria following trimethoprim-sulphamethoxazole in a lung cancer case treated by radiation therapy].
Topics: Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Combinations; Hemoglobinuria, Paroxy | 1987 |